Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
6.09
-0.03 (-0.49%)
At close: Apr 28, 2026, 4:00 PM EDT
6.19
+0.10 (1.64%)
After-hours: Apr 28, 2026, 7:41 PM EDT
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$670,908
Profits / Employee
$1,274
Market Cap
1.05B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| KalVista Pharmaceuticals | 275 |
| Xencor | 260 |
| Geron | 258 |
| uniQure | 221 |
| Omeros | 175 |
| Zenas BioPharma | 167 |
| Septerna | 130 |
| ORIC Pharmaceuticals | 104 |
XERS News
- 5 days ago - Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026 - Business Wire
- 25 days ago - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 6 weeks ago - Xeris Biopharma Holdings Transcript: Barclays 28th Annual Global Healthcare Conference - Transcripts
- 2 months ago - Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance - Business Wire
- 2 months ago - Why Are Shares Of Xeris Biopharma Falling Friday? - Benzinga
- 2 months ago - Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit - Business Wire
- 2 months ago - Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026 - Business Wire